Engineering bio-pharmaceutical micro- and nano-particles using supercritical carbon dioxide as anti-solvent

Schrift Standard Fett
Login

Forschungsstelle

INNOSUISSE

Projektnummer

7783.1;4 EPRP-IW

Projekttitel

Engineering bio-pharmaceutical micro- and nano-particles using supercritical carbon dioxide as anti-solvent

Projekttitel Englisch

Engineering bio-pharmaceutical micro- and nano-particles using supercritical carbon dioxide as anti-solvent

Texte zu diesem Projekt

	Deutsch	Französisch	Italienisch	Englisch
Kurzbeschreibung	-	-	-
Abstract	-	-	-

Erfasste Texte

Kategorie	Text
Kurzbeschreibung (Englisch)	Engineering bio-pharmaceutical micro- and nano-particles using supercritical carbon dioxide as anti-solvent
Abstract (Englisch)	The project deals with the Precipitation with Compressed Antisolvent (PCA) technique, i.e. a particle formation process that exploits the properties of a dense gas, typically near-critical carbon dioxide, to precipitate the product out of an organic solution. The main goals are (i) to deepen the understanding of the science and technology of PCA through experimental and theoretical work, and (ii) to apply PCA to the formation of micro- and nano-particles of products of pharmaceutical relevance, more specifically to the precipitation of drug and drug-polymer-composites formulations for pulmonary delivery and controlled drug release, featuring enhanced solubility or surface coating for prevention of irritations or for taste masking purposes. Improvements in such technological areas would have a tremendous impact on the business of Novartis Pharma. ETH Zurich and Novartis Pharma have complementary expertise and are ideal partners to guarantee a high probability of success to the project.

Kategorie

Text

Kurzbeschreibung
(Englisch)

Engineering bio-pharmaceutical micro- and nano-particles using supercritical carbon dioxide as anti-solvent

Abstract
(Englisch)

The project deals with the Precipitation with Compressed Antisolvent (PCA) technique, i.e. a particle formation process that exploits the properties of a dense gas, typically near-critical carbon dioxide, to precipitate the product out of an organic solution. The main goals are (i) to deepen the understanding of the science and technology of PCA through experimental and theoretical work, and (ii) to apply PCA to the formation of micro- and nano-particles of products of pharmaceutical relevance, more specifically to the precipitation of drug and drug-polymer-composites formulations for pulmonary delivery and controlled drug release, featuring enhanced solubility or surface coating for prevention of irritations or for taste masking purposes. Improvements in such technological areas would have a tremendous impact on the business of Novartis Pharma. ETH Zurich and Novartis Pharma have complementary expertise and are ideal partners to guarantee a high probability of success to the project.